• Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
  Published on 2024-01-10
  2 years ago
• Effects of open access publishing on article metrics in Neuropsychopharmacology
  Published on 2024-01-10
  2 years ago
• Correction: The effects of experience of discrimination and acculturation during pregnancy on the developing offspring brain
  Published on 2024-01-10
  2 years ago
• Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder
  Published on 2024-01-09
  2 years ago
• Neurogenesis-independent mechanisms of MRI-detectable hippocampal volume increase following electroconvulsive stimulation
  Published on 2024-01-08
  2 years ago
• Advances in precision neuromodulation: electroconvulsive therapy amplitude titration
  Published on 2024-01-08
  2 years ago
• Academic ethics of mental health: the national black postdocs framework for the addressment of support for undergraduate and graduate trainees
  Published on 2024-01-07
  2 years ago

« Previous 1 … 70 71 72 73 74 … 143 Next »

• A phase 1 study to assess potential interaction between ASP8062 and alcohol in healthy adult subjects
  Published on 2022-01-07
  4 years ago
• Incident infection during the first year of treatment – A comparison of clozapine and paliperidone palmitate long-acting injection
  Published on 2022-01-07
  4 years ago
• Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes
  Published on 2022-01-05
  4 years ago
• Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
  Published on 2022-01-05
  4 years ago
• MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults
  Published on 2022-01-05
  4 years ago
• The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation
  Published on 2022-01-04
  4 years ago
• Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia
  Published on 2022-01-04
  4 years ago

« Previous 1 … 70 71 72 73 74 … 134 Next »

• Corrigendum to ‘BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression’ European Neuropsychopharmacology Volume 58, May 2022, Pages 103-108
  Published on 2022-06-24
  3 years ago
• Editorial Board
  Published on 2022-06-24
  3 years ago
• Invisible wounds: Suturing the gap between the neurobiology, conventional and emerging therapies for posttraumatic stress disorder
  Published on 2022-06-17
  4 years ago
• Requiem or resurrection: Classic monoamine oxidase inhibitors revisited
  Published on 2022-06-14
  4 years ago
• A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia
  Published on 2022-06-12
  4 years ago
• Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the art
  Published on 2022-06-04
  4 years ago
• A pacemaker for happiness – Transcutaneous vagus nerve stimulation in depression
  Published on 2022-06-03
  4 years ago

« Previous 1 … 70 71 72 73 74 … 154 Next »